JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - X4 PHARMACEUTICALS INC
Do you want me to go? Good afternoon, everyone. My name's Adam Craig. I'm the executive chairman of X4, a Boston-based biotech company specializing in rare hematology. First, I'd like to thank Jeffress for the invitation to be here today. It's a pleasure to be back in this room after several years. We'll be making some forward-looking statements today. I'll refer you to the text in this slide. so x4 is focused on maximizing the potential of cx4 antagonism without the compound maverixifor which we're studying in the rare hematology hematologic condition primary chronic neutropenia over the last couple of years x4 has undergone a lot of change corporate change with new with restructuring with new management and we've now got to the point where we're very close to finishing enrollment on our pivotal phase 3 trial, the forward trial, in primary chronic neutropenia. If we complete enrollment by the end of this year, we expect to have data in the first quarter of 2028. So CXCR4 antagonism is a very simple concept, by the CXAR4 is responsible for the migration of neutrophils from the bone marrow into the bloodstream. And if you antagonize that target, the bone marrow releases neutrophiles into the bloodstream, and it's this concept that we believe will lead to an infection benefit, a decrease in infection in patients on our forward trial. Patients who have very low ANCs when they come on trial. And I'll explain that in a little bit. So patients with primary chronic neutropenia represent an unmet medical need. They live difficult lives. They have multiple infections. They Have difficulty socializing. And currently, the only available therapy, therapies available are antibiotics to treat the infections and prophylactic antibiotics to decrease infections, and GCSF. And as many of you know, GCSP is an injection, and it can be uncomfortable to give injections. It can cause bone pain. Patients have fatigue. And one of the most striking things you'll see from the data I'll present to you shortly is many patients with primary chronic neutropenia are young, and they don't want to be on GCSV for decades because there is a risk of malignant transformation to MDS and potentially AML. So this graphic here just basically illustrates that the lower your ANC, the higher the risk of infection. And if you look on the left-hand column, what you'll see is we describe severe and moderate ANC. Moderate being an ANC less than 1,000, severe being less than 500. If I got a syringe out and took blood from you all now, most people in this room would have an ANC over 1,500. And that would afford you protection against infection on a day-to-day basis. That's not the case for the primary chronic neutropenia, particularly the moderate and severe disease patients. They're at high risk of infection in day-To-day life. The kind of infections they get can be widespread. They can get chest infections, sinus infections, they can get boils under the skin, abscesses, it's all over. And the life of a primary chronic uterine pneumonia can be very limited because of the concerns about going out into the world and getting infections. So there is a desire for new therapy and when we talk to patients and we ask them what you want, they want their lives back. They want to live a life where they're not so restricted. It's almost like during COVID where people didn't go out because they were concerned about infection. It's that kind of scenario. And the one thing they do want is neural therapy, which I'll go into in detail. At the moment, they've got antibiotics, which can cause toxicity, as we know, can cause problems with long-term resistance, or they've Got injections with GCSF. Neither of those options are ideal. So if we can move forward and get maverixifor approved, we'll have an oral therapy in this setting, and I think that will be quite groundbreaking. So our clinical program currently involves two trials. The first trial, one phase 3 and one phase 2. But what led us to conducting these trials was a small phase 2 that was conducted in 23 patients, where we basically looked at two things. we looked at, can Maverix A4 increase the ANC in patients who have low ANCs? And then the other side of the question was, if you are maintaining a decent ANC on GCSF, can you reduce the GCSV dose or potentially remove GCSR and still maintain a decent AMC? So they're the two things we tested in this 23-patient trial. So as you can see on the right, or left, you'll see the demographic, the baseline characteristics of the 23. And then on the right, you'll see that 10 were monotherapy and 13 patients had received GCSF. So quite simply, if you start with the monotherapy patients who had low ANCs, we can see over a three, six-month period that normal ANCs can be maintained when maverixifor is introduced, and in this case, over 1,500 or more, which is the normal level. Remember, some of these patients have ANCs of 500, most of them are less than 1,000 before they start the trial. So the next question we asked was, as I said, can we reduce the GCSF dose? Because one of the attractions of maveritzifor, is we could potentially replace some of the use of GCSF in the marketplace or reduce its use, which with the bone pain, the discomfort infections, risk of malignancy would be an advantage for patients. And we found in this small study, and we're going to test it a bit further, I'll explain in a few minutes, but we found in this trial that about 70% of GGSF dosing was reduced, and in a number of patients were able to eliminate GCSR completely. That's quite a significant finding, considering that GCSF was approved 30 years ago, and it's really been the primary treatment for these patients. From a toxicity point of view, this drug is well tolerated. We do get some GI toxicity in the first few weeks of therapy. It can be treated with over-the-counter medication, and we're finding in the current trial this really is not a problem because we've learned as a company, how to manage it. And as long as patients were informed in advance they could get some GI toxicity and they should take drugs like loperamide if they have antidiarrheals, we found that this has not been a great concern. So this is our Phase III forward trial. The trial I was referring to, this will, if successful, will be part of an SNDA application for primary chronic neutropenia. We already have, for Mavarixifor, an approval for an ultra-rare condition called WIM, which is a form of severe neutropenia, but this is for a broader population. And it's a double-blinded placebo-controlled trial where we look at reduction in infection and increase ANC as the co-primary endpoints over a 12-month period. And that's why if we complete enrolment as we expect to by the end of this year. We will have a one-year follow-up and then day two in the early part of 2028. So the two endpoints are well powered for sample size 126. The reduction in infection, it's powered for at least a 30% reduction in affection, and that's 89% power. And then the ANC, which is a increase of ANC of 500 cells per microliter on at least three occasions over that 12-month period. That's, again, about a 30% increase in ANC, and that's 93% powering. Now, we've been asked consistently by investors, how are we doing? And obviously, the data is blinded, but we did think it was useful recently, our investor day two or three weeks ago, to share some data and give you an idea of the kind of patients we're getting. I already mentioned to you that many primary chronic uteropenia patients are young, And you can see here the median age coming on this study is 36 years, a pretty young population. About 37% of patients are on GCSF, so they're randomized on the study between Mavericks for plus or minus GCSV and then placebo plus or menos GCSR, and in the GCSL randomization, there's 37% patients. the median ANC on trial is 583 which me which puts the median in the severe bracket remember it's 500 or less to be defined as severe primary chronic neutropenia and that's important the FDA were very proud to the joint we joined as a management team the FDA communicated of the company, it's very important that we enrol a population in whom we can show a difference. And I'm pleased to see that we are enrolling patients who have ANC, a median ANC of 583. And then finally, along the same line, 68% of patients have three or more infections. Get on the trial. You need two infections in the prior 12 months. If we have patients who are actually having more than that, again, we have a sick population in which we can show a difference now one of the limitations of the forward trial we've always recognized it is the forward trail you can't change your gcsf dose the fda wanted us to fix the dose of gcsv throughout the whole study so one of things that will be missing the first day for the reps unless we fill that gap is uh the some communication some data on how you change the gcs f dose if you start maverixifor and you eventually want to potentially get off GCSF. So, oh, sorry, my apologies. So what we designed was the four-steps trial, brilliantly named by one of our team because it involves patients going on GCSR plus maveritzifor, an eight-week running period, and then a period over 24 weeks where patients can reduce the dose, physicians can reduce their patient's dose of GCSF by 25% in four steps. So the idea of this trial is to show that once maverixifor is initiated, that you can reduce the GCSV and ideally keep a patient at the end of it on an oral therapy with relatively low toxicity and remove the need for the painful, unpleasant GCSR injections. so the data for that the trial the trial is due to start uh enroll the first patient early next year and we'd expect the data the primary data to be out in the first quarter of 2028 so if you ask physicians what do they want here and if we we did a survey of physicians in the footnotes you can see who we spoke to community and academic physicians and ask them is the profile mavericks are for attractive it confirms what we believe you know they want to see something that is differentiated from gcsf they want something that is an oral therapy and the data we received back from the survey was they will prescribe it if we're successful and that's what we thought we thought this market is prime primed for a new therapy particularly an oral therapy. So how many patients are there? Probably the commonest question we get from investors after how is the study powered? And the answer is it depends on the label. If we have a label that fits exactly to the study, which is patients have to have two or more infections before coming on maverixifor, we think there's 15,000 patients. If the label just says symptomatic patients, as it does for the Neupogen label, then the potential market is double, up to 30,000 patients. And that's out of an overall primary chronic neutropenia population of 95,000 patients, which you see at the bottom here, for patients over the age of 12. So you can see that we really, for a small company in Boston with less than 50 employees, the potential here for the company is really quite substantial. and the potential to do good for a lot of patients is there. So, a quick corporate overview from a cash perspective. We had last reported 187 million in cash. We have 144 million shares outstanding. Many of them are held in this room. So, to finish off, we're a company, a small company, that's gone under a lot of change recently but we are now primarily focused on completing the forward trial with the new seed suite with the right investors and with the aim of getting a second approval in chronic neutropenia our cash runway will go into 2029 we will report the four steps data in early 2028 so that the first day of launch, which will either be the end of 28 or the early 29, our reps and our MSLs will have a document in their hands so they can guide physicians on how to use the drug in combination with GCSF. So the forward trial is near completing enrollment, and we expect to complete that by the end of the year, which meant there's a 12-month follow-up and then data early part of 2028. I promised a short presentation. With that, I'll stop. Thank you for your time. Thank you very much. Does anyone have any questions? Any questions? Okay. I think we're good. Thank you.
- Company
- X4 PHARMACEUTICALS INC
- Keywords
- X4 PHARMACEUTICALS INC